SKVI – A Closer Look

Skinvisible, Inc. (OTCBB: SKVI)

When you look at a Pharmaceutical Company for a serious investment it is important to examine where they are in the research & development of their technology and then the products that incorporate the technology.  That’s what makes SKVI such an outstanding investment with it’s patented technology Invisicare®.  Yesterday we saw an additional patent grant on Invisicare in Hong Kong.  The Company’s growing proprietary position is continually expanding internationally through patents.

SKVI’s new Hong Kong Patent covers its unique polymer delivery system, Invisicare(R).  This comprehensive patent is the fourth granted in Asia and the ninth worldwide. The Invisicare patent adds protection in Hong Kong in the areas of “Topical Composition,” “Topical Composition Precursor,” and “Methods for Manufacturing and Using.”

Skinvisible’s value lies in its ability to continually generate new intellectual property pertaining to dermatology and medical products formulated with Invisicare®. Additionally Patent approvals are being sought both in the United States and internationally for all products developed using Invisicare.

There are nine patents approved, including three in the US, and internationally in China, India, Australia, Japan, Korea and Hong Kong . There are a number of U.S. patents pending in addition to PCTs internationally, with many more to be filed. Some of these PCT patents cover up to five products. All patents with Invisicare are owned by Skinvisible.

•            Six approved international technology patents including India, Australia, China, Japan, Korea and Hong Kong

•            Nine U.S. product specific patents pending

•            34 international PCTs patents pending

What this means is with SKVI you have a technology with a broad application — Invisicare protected by international patents and able to continually generate revenue from Licensing Agreements, royalties and ON GOING Invisicare sales.

You get a good idea of the direction and the potential for SKVI when you examine their recent licensing agreements with RHEI.  These exclusive licensing agreements between Skinvisible and RHEI Pharmaceuticals HK Ltd., a Hong Kong-based pharmaceutical company and a subsidiary of Luxembourg-based Leeward Ventures SICAR SCA for the commercial/institutional rights for 3 formulations in the EU, China and US and DermSafe® hand sanitizer lotion for the EU and China.

For the EU, China & US only they are:

1.            an Incontinence Lotion that not only protects the skin against the irritation caused by urine & feces but also contains an ingredient that inhibits the enzymes that attack & digest the skin.

2.            a Barrier Hand Lotion that forms a protective barrier between the skin and the chemicals including hand soaps that come in contact with the skin everyday.

3.            a Super Moisturizer Hand Lotion with the ingredient Ectoin. Ectoin forms hydration shields around the skins cells keeping the cells working and fosters true moisturization, even under harsh conditions.

For the EU & China:

DermSafe, a Hand Sanitizer Lotion using Chlorhexidine Gluconate (CHG) as the active ingredient. CHG is widely used in healthcare facilities world wide as a hand soap and scrub soap in operating rooms. It is effective against gram positive & gram negative bacteria as well as viruses and fungi.  This product was developed as a replacement or adjunct to the alcohol sanitizers which are a Billion Dollar market in the US alone. The product which was developed with Invisicare binds to the skin and stays on for over 4 hours – even after hand washing – a real plus compared to alcohol sanitizers which are instant only and offer no long term benefit. Due to continual daily use of the alcohol sanitizers many in the healthcare industry personnel now have major hand health issues like dermatitis.

Invisicare (R) has multiple benefits – first it is the ingredient that holds the product together in the form of a gel or lotion– secondly it binds the product to the outer layer of the skin as a film former while still allowing the skin to breathe – and thirdly, Invisicare offers the benefit of  providing a controlled release of the active ingredient onto the skin.

Invisicare has the ability to be useful in multiple topical applications.  What this means for the Company is that Invisicare can be used to develop cosmetics, over-the-counter products and prescription products.   It also means unlimited licensing agreement revenue and ON GOING royalties in a broad range of product applications.

SKVI in essence the licenses the finished formulation to the pharmaceutical company for a specific  indication by territory while the patents offer them the protection they need to continue to have exclusivity for their products.  This represents the best of all possible situations for the pharmaceutical company and a huge range of potential customers for SKVI.

SKVI has a global reach with its international patents and an extremely broad ability to deliver multiple active ingredients in an Invisicare formulation with the potential to generate an incredible long term revenue stream.

Skinvisible, Inc. / Skinvisible Pharmaceuticals, Inc.

6320 S. Sandhill Road, Suite 10

Las Vegas, Nevada, 89120 U.S.A.

Phone: 702.433.7154

Fax: 702.433.7192


About Invisicare: Invisicare is Skinvisible’s patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. It is a combination of hydrophilic and hydrophobic polymers that hold active ingredients on the skin for extended periods of time resisting both wash off and perspiration. Invisicare can control the release of actives, reduce irritation and can eliminate some costly manufacturing processes. It is non-occlusive and allows for normal skin respiration while protecting against environmental irritants.

About Skinvisible Pharmaceuticals, Inc.

Skinvisible is a research-and-development company that licenses its proprietary formulations made with Invisicare, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time resisting both wash off and perspiration along with controlling the release of actives and reducing irritation. Skinvisible receives a combination of research and development fees, license fees, and royalties for the life of the patent. Skinvisible’s value also lies in its ability to continually generate new IP on topical products formulated with Invisicare.

StockGuru is STOCKGURU.COM. 1601 Berwick Drive, McKinney, Texas 75070 – (469) 252-3030. Disclosure: StockGuru entered into an investor relations consulting and market awareness contract on July 12, 2010. The company has agreed to pay us five thousand dollars per month in cash for the period of six months, totaling thirty thousand USD. StockGuru was previously compensated 500,000 144 restricted common shares by the company for profile coverage for the period ending January 30, 2010. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. To further clarify, we will not be buying or selling shares for the period of July 12, 2010 through January 12, 2011. We hold no shares and will not be receiving further compensation that is share related during this period. StockGuru is not a registered investment adviser or a broker/dealer. StockGuru makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.